CD4 and neoplasm: Since ENO1 is expressed on the tumor cell surface as a whole protein, inducing CD4+ T cells, the vaccine may also induce citENO1-specific B cells, resulting in antibody-dependent cellular cytotoxicity (ADCC) [45].